NASONEX

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Japan, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug NASONEX contains one active pharmaceutical ingredient (API):

1	Mometasone UNII MTW0WEG809 - MOMETASONE FUROATE MONOHYDRATE
	Mometasone is a topical glucocorticoid with local anti-inflammatory properties. It is likely that much of the mechanism for the effects of mometasone lies in its ability to inhibit the release of mediators of the inflammatory cascade.
	Read more about Mometasone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NASONEX Nasal spray	MPI, US: SPL/PLR	FDA, National Drug Code (US)
NASONEX Nasal Spray, Suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R01AD09	Mometasone	R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	527315120017617, 527315120017717
CA	Health Products and Food Branch	02238465
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00055509, 02193150, 05049548, 05120832, 10663256
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	22.376-1-08-05
EE	Ravimiamet	1028966, 1726501, 1726512, 1726523, 1820135, 1820168, 1823554, 1823587
ES	Centro de información online de medicamentos de la AEMPS	61905, BE190854, BE190854IP
FI	Lääkealan turvallisuus- ja kehittämiskeskus	474551, 474643
FR	Base de données publique des médicaments	63566855
GB	Medicines & Healthcare Products Regulatory Agency	139359, 143237, 26794
HK	Department of Health Drug Office	43556
HR	Agencija za lijekove i medicinske proizvode	HR-H-032470068
IE	Health Products Regulatory Authority	31587, 35235, 67120, 67145
JP	医薬品医療機器総合機構	1329710Q1027, 1329710Q2023
LT	Valstybinė vaistų kontrolės tarnyba	1003843, 1068854, 1077869, 1077870, 1079727, 1081256, 1082883, 1085547, 1085569, 1089255, 1089256
MT	Medicines Authority	MA031/01901, PI770/10401A, PI908/12702A
NL	Z-Index G-Standaard	14269961
NL	Z-Index G-Standaard, PRK	52434
NZ	Medicines and Medical Devices Safety Authority	7958
PL	Rejestru Produktów Leczniczych	100080562, 100157980, 100346267, 100351831, 100355964, 100363923, 100370544, 100384078, 100386634, 100460850, 100467170
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68334001, W68334002, W68334003, W68334004
SG	Health Sciences Authority	10763P
TN	Direction de la Pharmacie et du Médicament	6523111
US	FDA, National Drug Code	0085-1288
ZA	Health Products Regulatory Authority	32/21.5.1/0157, 36/21.5.1/0414